Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kyntra Bio Inc (KYNB : NSDQ)

• Company Description    Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Kyntra Bio, formerly known as FibroGen Inc., is based in SAN FRANCISCO. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $4.58 Daily Weekly Monthly 20 Day Moving Average: 23,046 shares Shares Outstanding: 4.05 (millions) Market Capitalization: $18.55 (millions) Beta: 1.05 52 Week High: $11.39 52 Week Low: $4.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -34.57% -33.88% 12 Week -32.55% -34.19% Year To Date -47.84% -46.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 350 Bay Street Suite 100 #6009 - SAN FRANCISCO,CA 94133 USA ph: 415-978-1200 fax: 415-978-1902 ir@kyntrabio.com http://www.kyntrabio.com

• General Corporate Information    Officers Thane Wettig - Chief Executive Officer James A. Schoeneck - Chairman of the Board and Director David DeLucia - Senior Vice President and Chief Financial Officer Jeffrey L. Edwards - Director Maykin Ho - Director Peer Information Kyntra Bio Inc (CORR.) Kyntra Bio Inc (RSPI) Kyntra Bio Inc (CGXP) Kyntra Bio Inc (BGEN) Kyntra Bio Inc (GTBP) Kyntra Bio Inc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31572Q881 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 4.05 Most Recent Split Date: 6.00 (0.04:1) Beta: 1.05 Market Capitalization: $18.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.91 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-16.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.49 EPS Growth vs. Year Ago Period: -38.46% vs. Previous Quarter: -25.13% Sales Growth vs. Year Ago Period: 36.47% vs. Previous Quarter: 192.49% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - - ROA 09/30/26 - - 06/30/26 - -47.27 03/31/26 - -36.71 Current Ratio 09/30/26 - - 06/30/26 - 2.69 03/31/26 - 3.61 Quick Ratio 09/30/26 - - 06/30/26 - 2.59 03/31/26 - 3.48 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - -671.32 Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - 2,199.13 Pre-Tax Margin 09/30/26 - - 06/30/26 - -669.42 03/31/26 - -761.59 Book Value 09/30/26 - - 06/30/26 - -7.32 03/31/26 - -7.60 Inventory Turnover 09/30/26 - - 06/30/26 - 1.20 03/31/26 - 1.19 Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - -

Powered by Zacks Investment Research ©